Page 106 - 《中国药房》2021年3期

[ 9 ] 卢克鹏，孟亚磊，王明乐，等.强化剂量与标准剂量的麦考 dosage regimen of mycophenolic acid is associated with
酚钠肠溶片用于肾移植术后免疫抑制治疗中有效性与 less acute rejection in kidney transplantation from dona-
安全性的 Meta 分析[J].中国医院药学杂志，2018，38 tion after circulatory death[J]. Urol Int，2018，101（4）：
（17）：1828-1832、1836. 443-449.
[10] BENTATA Y. Mycophenolates：the latest modern and po- [23] GELDER TV，HESSELINK DA. Mycophenolate revisi-
tent immunosuppressive drugs in adult kidney transplanta- ted[J]. Transpl Int，2015，28（5）：508-515.
tion：what we should know about them[J]. Artif Organs， [24] SANTANA DC，THEODOROPOULOS NM. Immuniza-
2020，44（6）：561-576. tion of solid organ transplant candidates and recipients：a
[11] HIGGINS JP，ALTMAN DG，GØTZSCHE PC，et al. The 2018 update[J]. Infect Dis Clin North Am，2018，32（3）：
Cochrane collaboration’s tool for assessing risk of bias in 517-533.
randomised trials[J]. BMJ，2011. DOI：10.1136/bmj.d5928. [25] MALVEZZI P，ROSTAING L. The safety of calcineurin
[12] STANG A. Critical evaluation of the Newcastle-Ottawa inhibitors for kidney-transplant patients[J]. Expert Opin
scale for the assessment of the quality of nonrandomized Drug Saf，2015，14（10）：1531-1546.
studies in meta-analyses[J]. Eur J Epidemiol，2010，25 [26] PAWINSKI T，DURLIK M，SZLASKA I，et al. Compari-
（9）：603-605. son of mycophenolic acid pharmacokinetic parameters in
[13] SEDGWICK P. Meta-analyses：what is heterogeneity[J]. kidney transplant patients within the first 3 months post-
BMJ，2015. DOI：10.1136/bmj.h1435. transplant[J]. J Clin Pharm Ther，2006，31（1）：27- 34.
[14] SEDGWICK P，MARSTON L. How to read a funnel plot
[27] SAINT-MARCOUX F，VANDIERDONCK S，PRÉMAUDA，
in a meta-analysis[J]. BMJ，2015. DOI：10.1136/bmj.h4718. et al. Large scale analysis of routine dose adjustments of
[15] PICHLMAYR A. Placebo-controlled study of mycopheno- mycophenolate mofetil based on global exposure in renal
late mofetil combined with cyclosporin and corticoste-
transplant patients[J]. Ther Drug Monit，2011，33（3）：
roids for prevention of acute rejection：European myco- 285-294.
phenolate mofetil cooperative study group[J]. Lancet， [28] SHAW LM，KORECKA M，VENKATARAMANAN R，
1995，345（8961）：1321-1325. et al. Mycophenolic acid pharmacodynamics and pharma-
[16] KEOWN P. A blinded，randomized clinical trial of myco-
cokinetics provide a basis for rational monitoring strate-
phenolate mofetil for the prevention of acute rejection in gies[J]. Am J Transplant，2003，3（5）：534-542.
cadaveric renal transplantation[J]. Transplantation，1996，
61（7）：1029-1037. [29] METZ DK，HOLFORD N，KAUSMAN JY，et al. Opti-
[17] NEYLAN JF. Immunosuppressive therapy in high-risk mizing mycophenolic acid exposure in kidney transplant
recipients：time for target concentration intervention[J].
transplant patients：dose-dependent efficacy of mycophe-
nolate mofetil in African-American renal allograft recipi- Transplantation，2019，103（10）：2012-2030.
ents：U.S. renal transplant mycophenolate mofetil study [30] FILLER G，FERRAND A. Do we need to worry about my-
cophenolate overdose[J]. Expert Opin Drug Saf，2014，13
group[J]. Transplantation，1997，64（9）：1277-1282.
[18] GLANDER P，SOMMERER C，ARNS W，et al. Pharma- （5）：521-524.
cokinetics and pharmacodynamics of intensified versus [31] KUYPERS DR，LE MEUR Y，CANTAROVICH M，et al.
standard dosing of mycophenolate sodium in renal trans- Consensus report on therapeutic drug monitoring of myco-
phenolic acid in solid organ transplantation[J]. Clin J Am
plant patients[J]. Clin J Am Soc Nephrol，2010，5（3）：
503-511. Soc Nephrol，2010，5（2）：341-358.
[19] GOURISHANKAR S，HOUDE I，KEOWN PA，et al. The [32] 田普训，敖建华，李宁，等.器官移植免疫抑制剂临床应用
clear study：a 5-day，3-g loading dose of mycophenolate 技术规范：2019版 [J].器官移植，2019，10（3）：213-226.
mofetil versus standard 2-g dosing in renal transplanta- [33] 王华彬，满江位，胡伟，等.霉酚酸血药浓度监测在肾移植
tion[J]. Clin J Am Soc Nephrol，2010，5（7）：1282-1289. 受者中的应用进展[J].医学综述，2020，26（4）：652-657.
[20] SOMMERER C，GLANDER P，ARNS W，et al. Safety [34] LI P，SHUKER N，HESSELINK DA，et al. Do Asian re-
and efficacy of intensified versus standard dosing regi- nal transplant patients need another mycophenolate
mens of enteric-coated mycophenolate sodium in de novo mofetil dose compared with Caucasian or African Ameri-
renal transplant patients[J]. Transplantation，2011，91（7）： can patients[J]. Transpl Int，2014，27（10）：994-1004.
779-785. [35] PACHECO E SILVA FILHO A，MANFRO RC，CONT-
[21] ZHANG H，LIU L，LI J，et al. The efficacy and safety of IERI FL，et al. Evaluation of tolerability of enteric-coated
intensified enteric-coated mycophenolate sodium with mycophenolate sodium versus mycophenolate mofetil in
low exposure of calcineurin inhibitors in Chinese de novo de novo renal transplantation[J]. J Bras Nefrol，2015，37
kidney transplant recipients：a prospective study[J]. Int J （3）：291-296.
Clin Pract，2016，6（70）：22-30. （收稿日期：2020-09-14 修回日期：2020-12-07）
[22] PENG W，LIU G，HUANG H，et al. Short-term intensified （编辑：陈 宏）

·352 · China Pharmacy 2021 Vol. 32 No. 3 中国药房 2021年第32卷第3期